Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36998152/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: These results show that treatment regimens including semaglutide 1.0 mg weekly lead to superior weight loss compared with liraglutide 3.0 mg daily for treating post-MBS weight recurrence, regardless of procedure type or the magnitude of weight recurrence.
Share
Phosphorylated proteomics-based analysis of the effects of semaglutide on hippocampi of high-fat diet-induced-obese mice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36998046/
The aim of this paper was to investigate the effects of semaglutide on phosphorylated protein expression, and its neuroprotective mechanism in hippocampi of high-fat-diet-induced obese mice. In total, 16 obese...
Conclusions/Relevance: This study demonstrates for the first time that semaglutide exerts neuroprotective effects by reducing HTT Ser1843, NEFH Ser 661 phosphorylation and increasing NEFL Ser 473 phosphorylation in hippocampal tissue of obese mice.
Share
This is used for those patients with obesity and they have an ample weight loss as experience from the weekly use of the product
Share
Once-Weekly Semaglutide in Adolescents with Obesity - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36322838/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Relevance: We were impressed that at week 68 the difference between the semaglutide group and the placebo group in the change in body-mass index was −16.7 percentage points and in body weight was −17.4 percentage points.
Share
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Source : https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00068-7/fulltext
Patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis are at particularly high risk of developing potentially life-threatening liver-related morbidities, such as portal hypertension, hepatic decompensation, hepatocellular carcinoma, liver-related mortality, and cardiovascular events.,...
Interpretation: In patients with NASH and compensated cirrhosis, semaglutide did not significantly improve fibrosis or achievement of NASH resolution versus placebo. No new safety concerns were raised.
Share